PODD
HealthcareInsulet Corporation
Price Chart
Market Data
Financials
XBRL · SEC EDGAR2011–2025(15yr)| Metric | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025Latest | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152.3M | $211.4M | $247.1M | $231.3M | $263.9M | $367.0M | $463.8M | $563.8M | $738.2M | $904.4M | $1.1B | $1.3B | $1.7B | $2.1B | $2.7B | +30.7% |
| Gross Profit | $66.7M | $92.3M | $112.4M | $143.3M | $148.2M | $211.1M | $277.2M | $370.2M | $480.3M | $582.3M | $752.1M | $805.6M | $1.2B | $1.4B | $1.9B | +34.2% |
| Gross Margin | 43.8% | 43.7% | 45.5% | 61.9% | 56.1% | 57.5% | 59.8% | 65.7% | 65.1% | 64.4% | 68.4% | 61.7% | 68.3% | 69.8% | 71.6% | +1.8pp |
| Operating Income | -$42.5M | -$36.0M | -$29.1M | -$12.3M | -$60.8M | -$10.7M | -$7.4M | $27.4M | $50.0M | $51.5M | $126.0M | $37.6M | $220.0M | $308.9M | $473.8M | +53.4% |
| Operating Margin | -27.9% | -17.0% | -11.8% | -5.3% | -23.0% | -2.9% | -1.6% | 4.9% | 6.8% | 5.7% | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% | +2.6pp |
| Net Income | -$57.2M | -$51.9M | -$45.0M | -$51.5M | -$73.5M | -$28.9M | -$26.8M | $3.3M | $11.6M | $6.8M | $16.8M | $4.6M | $206.3M | $418.3M | $247.1M | -40.9% |
| Net Margin | -37.5% | -24.5% | -18.2% | -22.3% | -27.9% | -7.9% | -5.8% | 0.6% | 1.6% | 0.8% | 1.5% | 0.4% | 12.2% | 20.2% | 9.1% | -11.1pp |
| Free Cash Flow | -$36.6M | -$40.0M | -$4.0M | -$2.6M | -$23.2M | -$6.2M | -$36.0M | -$126.5M | -$65.3M | -$45.0M | -$180.0M | -$3.9M | $70.1M | $305.4M | $377.7M | +23.7% |
| FCF Margin | -24.0% | -18.9% | -1.6% | -1.1% | -8.8% | -1.7% | -7.8% | -22.4% | -8.8% | -5.0% | -16.4% | -0.3% | 4.1% | 14.7% | 13.9% | -0.8pp |
| EPS (Diluted) | $-1.20 | $-1.07 | $-0.82 | $-0.91 | $-1.29 | $-0.48 | $-0.46 | $0.05 | $0.19 | $0.10 | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 | -39.8% |
1. THE BIG PICTURE
Insulet has successfully transitioned from a niche medical device maker into a high-growth category disruptor by decoupling insulin delivery from the "tubing" that defined the industry for decades. By combining a proprietary automated delivery algorithm with a disposable, recurring-revenue hardware model, Insulet Corporation is outgrowing established peers by nearly ten-to-one while maintaining gross margins that lead most of the sector.
2. WHERE THE RISKS HIT HARDEST
The "unprecedented freedom" of the tubeless Omnipod platform (10-K Item 1) is structurally threatened by Insulet’s extreme product concentration. Because Insulet Corporation derives nearly all revenue from this single platform, any failure in the "sole-sourced" supply chain for proprietary chips (10-K Item 1) would not just slow growth—it would jeopardize the entire $781.8 million quarterly revenue stream (8-K). Furthermore, the strategic push into the Type 2 diabetes market and the launch of Omnipod 5 are creating "operational scaling" risks; management warns that this rapid growth is straining manufacturing capacity, which could lead to an inability to meet the very demand Insulet Corporation is working to create.
3. WHAT THE NUMBERS SAY TOGETHER
While Insulet leads its peer group in revenue growth at 30.7% (XBRL), its bottom-line efficiency tells a different story. Insulet Corporation’s net margin of 9.0% is the lowest among its profitable peers, trailing Medtronic (13.9%) and ResMed (27.2%). This gap suggests Insulet is aggressively trading current profitability for scale. The most recent quarterly growth of 31.2% (8-K) is consistent with the TTMTTMTrailing Twelve Months — the most recent full year of financial data, updated on a rolling basis each quarter trend, but management’s 2026 guidance of 20% to 22% indicates a planned deceleration as Insulet Corporation laps the initial surge of the Omnipod 5 launch.
The market sentiment remains cautiously optimistic; short interest stands at 3.3% of the float, suggesting that while some investors are wary of the valuation, there is no broad consensus betting against the technology. The 16.3% Free Cash Flow margin (XBRL) confirms that despite high growth, the business is generating cash, which supports the Board’s recent $350 million increase in share repurchase authorization.
4. IS IT WORTH IT AT THIS PRICE?
At 29.4x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Insulet trades at a 29% premium to the peer median of 22.8x. This premium is supported by a revenue growth rate (+30.7%) that is nearly triple that of its closest high-growth peer, Edwards Lifesciences (+11.5%).
According to the (CAPM analysis), the current price implies a long-term growth rate of 9.0%. Given that Insulet is currently growing at more than 30% and is projecting 20%+ for 2026, the market’s "hurdle" for Insulet Corporation is actually quite low. If growth were to slow to a "Base" pace of 5.0%, the justified multiple would drop to 13.5x, representing significant downside. However, Insulet Corporation’s 70.8% gross margin—the second-highest in its peer group—provides a substantial buffer to absorb the costs of the upcoming Omnipod 6 and Type 2 product cycles.
5. WHAT WOULD CHANGE THIS VIEW?
- Cautious if gross margins contract below 65%, which would signal that "competitive pressure" from new patch-pump entrants or smart pens is forcing Insulet to sacrifice its premium pricing.
- Constructive if the "STRIVE" or "EVOLUTION 2" studies lead to a faster-than-expected FDA clearance for the Type 2 fully closed-loop system, opening a massive new patient demographic.
6. BOTTOM LINE
Structural Advantage: A proprietary, tubeless hardware-as-a-service model that creates high switching costs and a high-margin recurring revenue stream. Bottom Line: Insulet is an expensive but high-performing growth stock that is currently outrunning the relatively modest long-term expectations priced into its valuation.
1. Top 5 Material Risks
- Product Concentration: Insulet Corporation derives nearly all revenue from the Omnipod platform; failure to successfully market these products or retain the customer base would have a material adverse effect on business and results of operations.
- Customer Retention: Revenue growth depends on retaining a high percentage of customers; demand decreases caused by economic conditions, competition, or product performance issues would negatively impact revenue growth.
- Operational Scaling: Rapid growth, including the expansion of Omnipod 5 and entry into the type 2 diabetes market, may strain management and manufacturing capacity, potentially leading to an inability to deliver products in a timely manner.
- Reimbursement Dependency: Sales are limited if third-party payors (private insurance, Medicare, Medicaid) do not provide adequate coverage; contracts can generally be terminated without cause, and legislative changes to healthcare programs could adversely affect product pricing and demand.
- Competitive Pressure: Established insulin pump competitors and MDI therapy providers (including smart pens) may develop superior products or lower prices, which could lead to pricing pressure and decreased revenue for Insulet Corporation.
2. Company-Specific Risks
- Drug Delivery Agreement: Substantially all commercialized Drug Delivery revenue comes from a customized version of the product for Amgen’s Neulasta Onpro kit, an agreement that expires in December 2028.
- Supply Chain Concentration: Inventory is produced in a limited number of locations, including a third-party facility in China and a single U.S. location in Massachusetts, making Insulet Corporation vulnerable to regional disasters or geopolitical disruptions.
- Integration Dependencies: The functionality of Omnipod 5 relies on integration agreements with Dexcom and Abbott; the loss of these rights would prevent the sale of the product without significant development delays.
- Data Management Reliance: Insulet Corporation’s partnership with Glooko for cloud-based data management expires in December 2026; failure to renew or find an alternative would materially impact the business.
3. Regulatory/Legal Risks
- FDA Quality System Regulation (QSR): Insulet Corporation and its contract manufacturers must comply with complex QSR frameworks; failure to pass inspections or take timely corrective action can lead to production delays, fines, or injunctions.
- Off-Label Promotion: Promotional materials must comply with FDA regulations; if the FDA determines Insulet Corporation is promoting off-label use, Insulet Corporation could face warning letters, civil fines, or criminal penalties.
- Anti-Bribery Laws: Because most international customer relationships involve government-sponsored healthcare systems, Insulet Corporation is subject to the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act, where violations could disrupt business and result in criminal sanctions.
- Data Privacy: Insulet Corporation is subject to HIPAA, CCPA, CPRA, and GDPR; failure to comply with these evolving privacy and AI regulations could result in significant fines, monetary penalties, and restrictions on business practices.
4. Financial Impact Map
Product Concentration → Revenue → Nearly all revenue is derived from the Omnipod platform. Customer Retention → Revenue Growth → Failure to retain customers would negatively impact growth and results of operations. Operational Scaling → Results of Operations → Inability to scale manufacturing or manage resources would adversely affect results of operations. Reimbursement Dependency → Revenue and Pricing → Legislative changes to Medicare/Medicaid or loss of payor contracts could adversely affect demand and pricing. Competitive Pressure → Results of Operations → Pricing models or lower-priced competitor products could materially adversely impact results of operations.
Recent Filings
| Form | Filed | Period |
|---|---|---|
| 8-K | Feb 2026 | — |
| 10-K | Feb 2026 | Dec 2025 |
| 10-Q | Nov 2025 | Sep 2025 |
| 14A | Apr 2025 | — |
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
Insulet Appoints Mike Panos as EVP and Chief Commercial Officer to Lead Global Strategy
- ▸Mike Panos appointed as Executive Vice President and Chief Commercial Officer
- ▸Role oversees global commercial strategy, market access, and geographic expansion
- ▸Strategic focus remains on Omnipod 5 adoption and type 2 diabetes penetration
- ▸Company projects $4.7B revenue and $716.9M earnings by 2029
- ▸Requires 19.8% annual revenue growth to meet 2029 financial targets
Insulet Q4 revenue $783.8M, +31.2% YoY, beats analyst estimates by 2%
- ▸Q4 revenue $783.8M, +31.2% YoY, beating estimates by 2%
- ▸Insulet achieved fastest revenue growth among patient monitoring peer group
- ▸Patient monitoring sector Q4 revenues beat consensus estimates by 1.9%
- ▸Sector next-quarter revenue guidance 1.9% below analyst consensus
- ▸Insulet shares down 16% since Q4 earnings report
Insulet Voluntary Device Correction for Omnipod 5 Lots Expected to Have Limited Financial Impact
- ▸Voluntary device correction issued for specific Omnipod 5 lots
- ▸18 serious adverse events reported, including hospitalizations and DKA
- ▸No fatalities reported related to device correction
- ▸FY guidance remains unchanged; remediation costs excluded from non-GAAP results
- ▸EVOLUTION 2C study showed 68% time in range for type 2 diabetes patients
Insulet Q4 Revenue $783.8M +31.2% YoY, Beats Estimates; FY26 Revenue Growth Seen 20-22%
- ▸Q4 adjusted EPS $1.55, up 34.8% YoY, beating estimates by 4.87%
- ▸Q4 revenue $783.8M, up 31.2% YoY, exceeding guidance range of 25-28%
- ▸Omnipod revenue $781.8M, up 33.5% YoY; International growth 50.7%
- ▸FY26 revenue growth projected at 20-22% at constant exchange rates
- ▸Q4 operating margin 18.7%, expanding 36 basis points year over year